Related Experiment Video
Updated: Oct 14, 2025
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy
Hirofumi Suzumura1, Masashi Tsuruta2,3, Koji Okabayashi1
1Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Background/Aim:
The role of brahma-related gene 1 (BRG1)-associated factor 57 (BAF57), a transcription factor, has been determined in prostate, breast, and ovarian cancer. However, the relationship between BAF57 and colorectal cancer (CRC) is obscure. Thus, we examined the functional correlation between BAF57 expression and oncological malignancy in CRC in vitro.
Materials And Methods:
BAF57 expression in WiDr and HT29 CRC cell lines and clinical specimens from CRC patients was analysed by western blotting and/or RT-PCR. BAF57 expression was down-regulated in WiDr cells through siRNA transfection. An invasion assay was also performed to assess malignancy.
Results:
BAF57 was expressed in both human CRC cell lines. Overall survival and recurrence-free survival rates were significantly reduced in high BAF57-expressing specimens. BAF57 expression was an independent predictive factor for long-term survival.
Conclusion:
BAF57 correlates with oncological malignancy and may be a novel therapeutic target in CRC.
